Skip to content
lifestyle.tasteterminal.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Adagene Inc.
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
September 10, 2026
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
September 9, 2026
Adagene to Participate in Three Upcoming Investor Conferences
August 20, 2026
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
August 12, 2026
Adagene to Participate in Two Upcoming Investor Conferences
May 23, 2026
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
April 17, 2026
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
April 14, 2026
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
April 2, 2026
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
April 2, 2026
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
April 2, 2026
1
2
Next Page
→